MaxCyte, Inc. (MXCT)
| Market Cap | 132.83M |
| Revenue (ttm) | 32.29M |
| Net Income (ttm) | -39.12M |
| Shares Out | 107.12M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 364,950 |
| Open | 1.250 |
| Previous Close | 1.240 |
| Day's Range | 1.240 - 1.290 |
| 52-Week Range | 0.643 - 2.370 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 4.11 (+231.45%) |
| Earnings Date | Aug 5, 2026 |
About MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engi... [Read more]
Financial Performance
In 2025, MaxCyte's revenue was $33.03 million, a decrease of -14.50% compared to the previous year's $38.63 million. Losses were -$44.63 million, 8.71% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MXCT stock is "Buy." The 12-month stock price target is $4.11, which is an increase of 231.45% from the latest price.
News
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering
ROCKVILLE, Md. & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing ena...
MaxCyte reports Q1 EPS (4c), consensus (9c)
Reports Q1 revenue $9.65M, consensus $7.3M. “We are pleased with our performance in the first quarter, and remain confident in our full year guidance,” said Maher Masoud, President and CEO…
MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
The company said, “MaxCyte (MXCT) expects to end 2026 with at least $136 million in total cash, cash equivalents and investments, which does not include capital to be used for…
MaxCyte Earnings Call Transcript: Q1 2026
Q1 2026 revenue met expectations but declined year-over-year due to SPL program turnover and inventory management. Guidance for 2026 is reiterated, with revenue weighted to the second half and a $10 million share repurchase program authorized.
MaxCyte Earnings release: Q1 2026
MaxCyte released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
MaxCyte Quarterly report: Q1 2026
MaxCyte has published its Q1 2026 quarterly earnings report on May 12, 2026.
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core r...
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, develop...
MaxCyte Proxy statement: Proxy filing
MaxCyte filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MaxCyte Proxy statement: Proxy filing
MaxCyte filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, developme...
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on MaxCyte (MXCT) to $5 from $7 and keeps a Buy rating on the shares. The firm notes the company reported an ostensibly weak…
MaxCyte Earnings Call Transcript: Q4 2025
2025 saw revenue decline 15% year-over-year amid SPL program exits and inventory headwinds, but new product launches, cost restructuring, and a strong balance sheet position the company for growth. 2026 guidance anticipates $30–32 million in revenue, with a back-half weighted recovery and material contributions from SeQure Dx and SPL milestones.
MaxCyte Annual report: Q4 2025
MaxCyte has published its Q4 2025 annual report on March 24, 2026.
MaxCyte Earnings release: Q4 2025
MaxCyte released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
The company said, “MaxCyte (MXCT) expects to end 2026 with at least $136 million in total cash, cash equivalents and investments.”
MaxCyte reports Q4 EPS (9c), consensus (8c)
Reports Q4 revenue $7.3M, consensus $9.16M. “Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which…
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary ...
MaxCyte Slides: Corporate presentation
MaxCyte has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
MaxCyte Slides: Investor presentation
MaxCyte has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
MaxCyte appoints Parmeet Ahuja as CFO
MaxCyte (MXCT) announced that it has appointed Parmeet Ahuja as CFO, effective March 30. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, developme...
MaxCyte announced the launch of ExPERT DTx
MaxCyte (MXCT) announced the launch of ExPERT DTx, a new high throughput transfection platform for research and drug discovery applications. “We’re extremely excited about the launch of the ExPERT DTx...
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developm...